Isoray’s lunch symposium, Eliminate Uncertainty, Increase Precision & Reduce Toxicity, will be a presentation by Dr. Stephen J. Frank, MD, FABS, MD Anderson Cancer Center, Department of Radiation Oncology.

During the conference, the Prostate Snap Oral I scientific session included two abstracts that were presented by The Cesium Advisory Group. The group is comprised of five experienced physicians with extensive experience…

Revenue for the third quarter of fiscal 2022 grew 12% to $2.91 million versus $2.60 million in the prior year comparable period.

To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011.

A live webcast of the virtual fireside chat will be available on Isoray’s Investor Relations section of the Company’s website at https://isoray.com/investors/presentations/.

The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution, was authored by Joshua L. Rodríguez-López, MD, Ankur K. Patel, MD, Ronald M. Benoit, MD, Sushil Beriwal, MD, Ryan P. Smith, MD, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Revenue for the second quarter of fiscal 2022 grew 19% to $2.82 million versus $2.36 million in the prior year comparable period.

To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011.

Revenue for the first quarter of fiscal 2022 grew 8% to $2.56 million versus $2.38 million in the prior year comparable period.

To listen to the conference call, please dial (888) 506-0062. For callers outside the U.S., please dial (973) 528-0011.

ABS does not rank or endorse any specific treatment option, but rather is focused on evaluating evidence and providing insight into research surrounding the use of brachytherapy in addressing malignant and benign conditions.

The rescheduled conference call was necessitated by the conference bridge provider’s technical failure.